Trial | NCT02202928  Report issue

Title

Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    60
The purpose of this study is to evaluate the efficacy of autologous tumor lysate-pulsed dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).
60 patients with stageⅠ~ Ⅲ CRC, who had received surgery and kept their tumor tissue, will be randomly divided into group A (receive DC-CIK treatment, chemotherapy and radiotherapy) or group B (just receive chemotherapy and radiotherapy), and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of autologous tumor lysate pulsed DC-CIK cells treatment (every 4 weeks) and 4 cycles chemo-radiotherapy. Patients in group B will receive only 4 cycles chemo-radiotherapy.
Study Started
Jul 31
2014
Primary Completion
Dec 31
2017
Anticipated
Study Completion
Dec 31
2017
Anticipated
Last Update
Dec 28
2015
Estimate

Biological DC-CIK

8×10^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.

Radiation Radiotherapy

45~50 Gy in 25-28 fractions.

Drug Chemotherapy

Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.

  • Other names: FOLFOX

Chemo-radiotherapy Sham Comparator

After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will just regularly follow up.

DC-CIK Experimental

After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will receive 3 cycles of autologous tumor lysate pulsed DC-CIK treatment.

Criteria 

Inclusion Criteria:

18~80 years old;
Histologically confirmed with colorectal cancer at stage Ⅰ~Ⅲ;
Patients who can accept curative operations;
Patients who have a life expectancy of at least 3 months;
Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1.

Exclusion Criteria:

Hemoglobin<8.0 g/dL,Platelet count <75 x 10^9/L; ALT, AST, BUN and Cr more than normal limits on 3.0 times ;
Known or suspected allergy to the investigational agent or any agent given in association with this trial;
Pregnant or lactating patients;
Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection;
Patients who are suffering from serious autoimmune disease;
History of organ allograft;
Patients who had distant metastases;
Patients who had active infection;
Prior use of any anti-cancer treatment in 30 days;
Now or recently will join another experimental clinical study ;
Other situations that the researchers considered unsuitable for this study.
No Results Posted